20
Participants
Start Date
March 20, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER